About Stifel Financial Corp
- Industry: Financial Services
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.stifel.com/
Frequently Asked Questions
What is the 52-week range for SF?
The 52-week high is $89.83 and the 52-week low is $67.805.
What is the P/E ratio for SF?
The Price to Earnings (P/E) ratio is 11.10.
What is the dividend yield for SF?
The indicated annual dividend yield is 2.32%.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 16.07%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 14.25%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.13.
Analyst Recommendation Trends
Wall Street analyst consensus for SF over the last few months:
Latest SF News
1919 Investment Counsel Recognized Among Barron's 2026 Top 100 RIA Firms
1919 Investment Counsel, LLC ("1919"), a subsidiary of Stifel Financial Corp. ("Stifel"), is proud to announce its inclusion in Barron's 2026 Top 100 RIA Firms list. Ranked No. 33 nationally, 1919 has earned a place on the list for the seventh consecutive year, reflecting the firm's continued commitment to helping clients achieve their long-term financial goals.
Santhera first-half sales double as Stifel keeps ‘buy’ rating and CHF25 target
Stifel, the broker, has kept its ‘buy’ rating and CHF25 target price on Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss neuromuscular drugmaker, after first-half group revenue doubled to CHF48.3 million. The company left its 2026 guidance of CHF80 million to CHF90 million...
Top Bank Tweaks Microsoft Stock Price Target for 2027
Microsoft Stock Gets Surprise Upgrade as Stifel Sees Growth Back on Track
Wall Street doubles down on Microsoft stock for investors
Microsoft has been the quiet name in the AI trade all year, but that just changed.
This Is The Top REIT Stock Stifel Analysts Are Backing Right Now
Investing.com -- Stifel has highlighted its top stock selection in the real estate investment trust sector, featuring First Industrial Realty Trust as the firm’s current favorite idea from its equity research analysts.
Stifel Reports August 2026 Operating Data
ST. LOUIS, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today reported selected operating results for August 31, 2026, to provide timely information to investors on certain key performance metrics. Due to the limited nature of this data, a consistent correlation to earnings should not be assumed. Ronald J. Kruszewski, Chairman and Chief Executive Officer, said, “Total client assets and fee-based client assets reached record highs, increasing 12% and 17% year over year, ex
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
RADNOR, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that management will be participating in the Stifel 2026 Virtual Cardiometabolic Forum taking place on September 30, 2026. Stifel 202
Why These Wall Street Analysts Think Microsoft Stock Is ‘Getting Back on Track
Microsoft’s story may finally be gaining traction. Here’s why Stifel sees a path back to growth for MSFT.
3 US Broker Stocks Where Higher Rates Could Lift Interest Income
Interest rates are rising again, inflation is still sticky, and suddenly the sleepy corner of brokerage cash and margin lending looks anything but boring. When the Fed pushes the benchmark rate to a range of 3.75% to 4%, every idle dollar in a brokerage account and every margin loan starts to matter more to investors and to the brokers themselves. This article walks through three US retail broker-dealer stocks that screen as exposed to these crosscurrents, and explains how higher-for-longer...
Microsoft Stock Wins Upgrade. Why This Analyst Sees 15% Upside.
Microsoft stock momentum is expected to continue as OpenAI revenue contribution to Microsoft accelerates.
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
CAMBRIDGE, Mass., September 23, 2026--Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
Altimmune to Participate in Stifel Cardiometabolic Forum
GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET. A webcast of the fireside chat will be available via the Events section of the Altimmune website. About Altimmune Altimmune is a late clinic
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026 at 9:00am ET. The event will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcast will be available on
Why Micron Stock Popped This Morning
Expect another earnings beat from Micron next week -- a smaller beat, but still a beat.
NKE Stock In Focus After Stifel Lowers Price Target To $40 – A Look At Some Key Highlights
Stifel expects greater promotional activity in Western markets and a more challenging year-over-year gross margin comparison in the fiscal fourth quarter.
BRP (TSX:DOO) Stock Sees Fair Value Lift After Q2 Analyst Target Increases
BRP now carries a higher Fair Value Estimate of CA$103.07, up from CA$97.22, which lines up more closely with the Street price targets that have been cited after the latest update. Recent analyst commentary reflects this shift, with more upbeat views tying higher targets to Q2 execution and product momentum, while cautious voices still highlight tariff and valuation risks. As you read on, you will see how this evolving narrative around BRP may shape the way you track the stock from here. Stay...
Plains GP Holdings (PAGP) Stock Gets Fair Value Bump On Silver Creek And Q2 Revisions
Plains GP Holdings is under fresh scrutiny as fair value in one key model shifts from about US$24.93 to about US$25.77, a move that brings price targets into slightly higher territory. Recent analyst research connects this change to the Silver Creek Midstream acquisition, updated Q2 assumptions and the company’s Permian crude exposure, with views ranging from more constructive to still cautious. As you read on, you will see how to track these moving parts and keep up with the evolving story...
Stifel Financial (SF) Expands Venture Banking, Is The Upside Already Priced In?
Stifel Financial (SF) just moved to deepen its venture banking bench by bringing in three senior leaders with long Silicon Valley Bank and venture ecosystem experience across Boston, New York City, and the broader East Coast. Recent appointments in venture banking and European leveraged finance come after a choppy stretch for Stifel Financial’s stock. The share price at $75.79 has seen a 30 day share price return of negative 8.38 percent, while the 3 year total shareholder return of 91.07...
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
SAN DIEGO, September 17, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET.
Stifel Expands Venture Banking Presence Across East Coast With Senior Hires
Industry Veterans Appointed in New York and Boston, Augmenting Venture Banking and Venture Capital Coverage NationwideST. LOUIS, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced the addition of three senior leaders to its Venture Banking business, further solidifying its presence across the East Coast venture ecosystem. Chris Morrison, Matt Scott, and Arianne Perry, each of whom previously held senior roles at Silicon Valley Bank (“SVB”), join Stifel to expand
Recludix Pharma to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D., chief executive officer, and Ajay Nirula, M.D., Ph.D., president and head of research and development, will present an overview of the company at the Stifel 2026 Virtual Immunology and Inflammation Forum. The company’s presentation will be on Thursday, September 24
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:00 am EDT. To access the audio webcast and subsequent archived reco
1 Profitable Stock with Exciting Potential and 2 We Avoid
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Vicore Pharma to Present in The Stifel 2026 Virtual Immunology and Inflammation Forum
STOCKHOLM, SE / ACCESS Newswire / September 17, 2026 / AB (publ) (STO:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists, today announced that the company will participate in the Stifel 2026 Virtual Immunology and Inflammation Forum.Location: VirtualFormat: Presentation and 1×1 meetingsPresentation Date and Time: Thursday, September 24, 2026, 8:30-8:55 AM ETParticipants: Ahmed Mousa, CEO; Hans
CCL Stock Traders Stare At Sixth Red Week: Analysts Predict Weak Outlook On High Fuel Prices Ahead Of Q3 Earnings
Carnival faces mounting cost concerns as fuel prices climb, while retail sentiment stays neutral ahead of its Sept. 29 earnings report.
Braveheart Bio to Participate in Stifel Cardiometabolic Forum
SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will participate in the Stifel Virtual Cardiometabolic Forum, being held September 30. Management will participate in a fireside chat on Wednesday, September 30, 2026, at 12:30 p.m. EDT. Interested parties may access a live w
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced that members of its management team are scheduled to present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23 at 11
Energy Transfer’s (ET) Strong 2026 Run Gets a Fresh Vote from Stifel
Energy Transfer LP (NYSE:ET) has surged by almost 30% since the beginning of 2026, propelled by its strong performance, high natural gas demand in the US, and new pipeline opportunities from data centers. The stock has also now received a fresh vote of confidence from Wall Street. On September 10, Stifel resumed coverage of ET […]
KBW Announces Index Rebalancing for Third-Quarter 2026
NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Keefe, Bruyette & Woods, Inc., a leading specialist investment bank to the financial services and fintech sectors, and a wholly owned subsidiary of Stifel Financial Corp. (NYSE: SF), announces the upcoming index rebalancing for the third quarter of 2026. This quarter, there are constituent changes within one of our indexes: KBW Nasdaq Regional Banking Index (Index Ticker: KRX) These changes will be effective prior to the opening of business on Monday,
Stifel CEO Ron Kruszewski on AI as an Accelerator and Why Humans Still Win
Stifel CEO Ron Kruszewski joins Inside the ICE House to mark 30 years leading the 136-year-old firm and reflect on navigating constant change. He explains why he sees AI as a powerful accelerator rather than a replacement for human judgment, and why he's betting Stifel's business on the enduring value of human relationships. Kruszewski warns against chasing trends like tokenization without heeding the lessons of financial history, favoring a strategy of compounding capabilities over decades. He closes with his outlook on where AI and financial services are headed together.
Dividend Champion, Contender, And Challenger Highlights: Week September 13
Read this week's dividend recap for Dividend Champions, Contenders & Challengersâtrack dividend changes, upcoming ex-dividend dates & pay dates.
Stifel Deepens Fixed Income Platform with Senior Talent
Industry veterans Conor Daly and Jim Franz appointed Co-Heads of European Leveraged Finance SalesST. LOUIS & LONDON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced the appointments of Conor Daly and Jim Franz as Co-Heads of Leveraged Finance Sales in Europe, further strengthening the firm’s global Fixed Income platform. Based in London, Messrs. Daly and Franz bring five decades of combined experience in European leveraged finance, high yield and distressed c
A Look Back at Investment Banking & Brokerage Stocks’ Q2 Earnings: Stifel (NYSE:SF) Vs The Rest Of The Pack
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Stifel (NYSE:SF) and its peers.
Preliminary Agenda: 6th Palm Beach CorpGov Forum Nov 4-5 with Activism, Sports, VC
Watch Highlights From the 2025 Palm Beach CorpGov Forum: CorpGov, IPO Edge and PE Edge will host the sixth annual Palm Beach CorpGov Forum on November 4-5, 2026, at the Palm Beach Lake Pavilion and The Cove Club, both located waterfront with sweeping views of Palm Beach Island, along with a reception at Cucina Palm Beach. The Forum will […] The post Preliminary Agenda: 6th Palm Beach CorpGov Forum Nov 4-5 with Activism, Sports, VC appeared first on CorpGov.
Why Stifel Just Revamped Its Price Target for Microsoft Stock
Stifel lifted its Microsoft price target to $530 as Copilot adoption expands and Azure growth remains strong, adding to the bullish Wall Street view on MSFT stock.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-23 | Brown Maryam S. | -2,200 | $79.14 | $174,108 |
| 2026-07-23 | Brown Maryam S. | -2,500 | $79.25 | $198,125 |
| 2026-06-09 | Carnoy Lisa Landau | +2,450 | $71.4 | $174,930 |
| 2026-06-09 | Kavanaugh James P. | +2,450 | $71.4 | $174,930 |
| 2026-06-09 | Berlew Adam T. | +2,450 | $71.4 | $174,930 |
| 2026-06-09 | Brown Maryam S. | +2,450 | $71.4 | $174,930 |
| 2026-06-09 | Markus Maura A. | +2,450 | $71.4 | $174,930 |
| 2026-06-09 | Nesi Victor | +2,450 | $71.4 | $174,930 |
| 2026-06-09 | Grady Robert Edward | +2,450 | $71.4 | $174,930 |
| 2026-06-09 | PEACOCK DAVID A | +2,450 | $71.4 | $174,930 |
| 2026-06-09 | ZIMMERMAN MICHAEL J | +2,450 | $71.4 | $174,930 |
| 2026-06-09 | BROWN MICHAEL W | +2,450 | $71.4 | $174,930 |
| 2026-06-04 | Carnoy Lisa Landau | -2,812 | - | - |
| 2026-06-04 | Carnoy Lisa Landau | +2,812 | - | - |
| 2026-06-04 | Kavanaugh James P. | -2,812 | - | - |
| 2026-06-04 | Kavanaugh James P. | +2,812 | - | - |
| 2026-06-04 | Berlew Adam T. | -2,812 | - | - |
| 2026-06-04 | Berlew Adam T. | +2,812 | - | - |
| 2026-06-04 | Brown Maryam S. | -2,812 | - | - |
| 2026-06-04 | Brown Maryam S. | +2,812 | - | - |
| 2026-06-04 | Markus Maura A. | -2,812 | - | - |
| 2026-06-04 | Markus Maura A. | +2,812 | - | - |
| 2026-06-04 | PEACOCK DAVID A | -2,812 | - | - |
| 2026-06-04 | PEACOCK DAVID A | +2,812 | - | - |
| 2026-06-04 | ZIMMERMAN MICHAEL J | -2,812 | - | - |
| 2026-06-04 | ZIMMERMAN MICHAEL J | +2,812 | - | - |
| 2026-06-04 | BROWN MICHAEL W | -2,812 | - | - |
| 2026-06-04 | BROWN MICHAEL W | +2,812 | - | - |
| 2026-03-09 | Raymond Charles Bradford | -53,241 | - | - |
| 2026-03-09 | Raymond Charles Bradford | +60,673 | - | - |
| 2026-03-09 | Raymond Charles Bradford | -29,443 | $73.05 | $2,150,811 |
| 2026-03-09 | Raymond Charles Bradford | +53,241 | - | - |
| 2026-02-27 | Raymond Charles Bradford | +13,504 | $74.05 | $999,971 |
| 2026-02-27 | Raymond Charles Bradford | +12,694 | $74.05 | $939,991 |
| 2026-02-27 | Fisher Mark P | +5,402 | $74.05 | $400,018 |
| 2026-02-27 | Fisher Mark P | +9,723 | $74.05 | $719,988 |
| 2026-02-27 | Rubulotta David | +13,504 | $74.05 | $999,971 |
| 2026-02-27 | Rubulotta David | +10,533 | $74.05 | $779,969 |
| 2026-02-27 | McDuffie Brantley | +13,504 | $74.05 | $999,971 |
| 2026-02-27 | McDuffie Brantley | +10,533 | $74.05 | $779,969 |
| 2026-02-27 | Marischen James M | +5,402 | $74.05 | $400,018 |
| 2026-02-27 | Marischen James M | +9,723 | $74.05 | $719,988 |
| 2026-02-27 | Michaud Thomas B. | +13,504 | $74.05 | $999,971 |
| 2026-02-27 | Michaud Thomas B. | +17,623 | $74.05 | $1,304,983 |
| 2026-02-27 | SLINEY DAVID D | +5,402 | $74.05 | $400,018 |
| 2026-02-27 | SLINEY DAVID D | +12,424 | $74.05 | $919,997 |
| 2026-02-27 | ZEMLYAK JAMES M | +13,504 | $74.05 | $999,971 |
| 2026-02-27 | ZEMLYAK JAMES M | +25,388 | $74.05 | $1,879,981 |
| 2026-02-27 | KRUSZEWSKI RONALD J | +27,009 | $74.05 | $2,000,016 |
| 2026-02-27 | KRUSZEWSKI RONALD J | +39,163 | $74.03 | $2,899,237 |
| 2026-02-27 | REICHERT CHRISTOPHER K | +4,051 | $74.05 | $299,977 |
| 2026-02-27 | REICHERT CHRISTOPHER K | +5,402 | $74.05 | $400,018 |
| 2026-02-18 | Marischen James M | -7,859 | - | - |
| 2026-02-18 | Marischen James M | +9,823 | - | - |
| 2026-02-18 | Marischen James M | -3,463 | $120.49 | $417,257 |
| 2026-02-18 | Marischen James M | +7,859 | - | - |
| 2026-02-18 | Nesi Victor | -36,981 | - | - |
| 2026-02-18 | Nesi Victor | +46,227 | - | - |
| 2026-02-18 | Nesi Victor | -18,879 | $120.49 | $2,274,731 |
| 2026-02-18 | Nesi Victor | +36,981 | - | - |
| 2026-02-18 | Michaud Thomas B. | -16,179 | - | - |
| 2026-02-18 | Michaud Thomas B. | +20,224 | - | - |
| 2026-02-18 | Michaud Thomas B. | -7,983 | $120.49 | $961,872 |
| 2026-02-18 | Michaud Thomas B. | +16,179 | - | - |
| 2026-02-18 | Fisher Mark P | -7,859 | - | - |
| 2026-02-18 | Fisher Mark P | +9,823 | - | - |
| 2026-02-18 | Fisher Mark P | -4,241 | $120.49 | $510,998 |
| 2026-02-18 | Fisher Mark P | +7,859 | - | - |
| 2026-02-18 | WEISEL THOMAS W | -4,623 | - | - |
| 2026-02-18 | WEISEL THOMAS W | +5,778 | - | - |
| 2026-02-18 | WEISEL THOMAS W | -1,693 | $120.49 | $203,990 |
| 2026-02-18 | WEISEL THOMAS W | +4,623 | - | - |
| 2026-02-18 | SLINEY DAVID D | -11,094 | - | - |
| 2026-02-18 | SLINEY DAVID D | +13,868 | - | - |
| 2026-02-18 | SLINEY DAVID D | -4,887 | $120.49 | $588,835 |
| 2026-02-18 | SLINEY DAVID D | +11,094 | - | - |
| 2026-02-18 | ZEMLYAK JAMES M | -31,434 | - | - |
| 2026-02-18 | ZEMLYAK JAMES M | +39,293 | - | - |
| 2026-02-18 | ZEMLYAK JAMES M | -13,847 | $120.49 | $1,668,425 |
| 2026-02-18 | ZEMLYAK JAMES M | +31,434 | - | - |
| 2026-02-18 | KRUSZEWSKI RONALD J | -73,963 | - | - |
| 2026-02-18 | KRUSZEWSKI RONALD J | +92,453 | - | - |
| 2026-02-18 | KRUSZEWSKI RONALD J | -32,581 | $120.49 | $3,925,685 |
| 2026-02-18 | KRUSZEWSKI RONALD J | +73,963 | - | - |
| 2026-02-18 | REICHERT CHRISTOPHER K | -7,396 | - | - |
| 2026-02-18 | REICHERT CHRISTOPHER K | +9,245 | - | - |
| 2026-02-18 | REICHERT CHRISTOPHER K | -3,261 | $120.49 | $392,918 |
| 2026-02-18 | REICHERT CHRISTOPHER K | +7,396 | - | - |
| 2026-02-02 | Rubulotta David | -400 | $124.31 | $49,724 |
| 2026-01-30 | Marischen James M | -1,568 | - | - |
| 2026-01-30 | Marischen James M | -691 | $126.24 | $87,232 |
| 2026-01-30 | Marischen James M | +1,568 | - | - |
| 2026-01-30 | Nesi Victor | -6,898 | - | - |
| 2026-01-30 | Nesi Victor | -3,522 | $126.24 | $444,617 |
| 2026-01-30 | Nesi Victor | +6,898 | - | - |
| 2026-01-30 | Michaud Thomas B. | -2,665 | - | - |
| 2026-01-30 | Michaud Thomas B. | -1,315 | $126.24 | $166,006 |
| 2026-01-30 | Michaud Thomas B. | +2,665 | - | - |
| 2026-01-30 | Fisher Mark P | -1,725 | - | - |
| 2026-01-30 | Fisher Mark P | -931 | $126.24 | $117,529 |
| 2026-01-30 | Fisher Mark P | +1,725 | - | - |
| 2026-01-30 | WEISEL THOMAS W | -628 | - | - |
| 2026-01-30 | WEISEL THOMAS W | -260 | $126.24 | $32,822 |
| 2026-01-30 | WEISEL THOMAS W | +628 | - | - |
| 2026-01-30 | SLINEY DAVID D | -2,258 | - | - |
| 2026-01-30 | SLINEY DAVID D | -995 | $126.24 | $125,609 |
| 2026-01-30 | SLINEY DAVID D | +2,258 | - | - |
| 2026-01-30 | KRUSZEWSKI RONALD J | -12,542 | - | - |
| 2026-01-30 | KRUSZEWSKI RONALD J | -5,525 | $126.24 | $697,476 |
| 2026-01-30 | KRUSZEWSKI RONALD J | +12,542 | - | - |
| 2026-01-30 | REICHERT CHRISTOPHER K | -1,568 | - | - |
| 2026-01-30 | REICHERT CHRISTOPHER K | -694 | $126.24 | $87,611 |
| 2026-01-30 | REICHERT CHRISTOPHER K | +1,568 | - | - |
| 2026-01-30 | ZEMLYAK JAMES M | -5,644 | - | - |
| 2026-01-30 | ZEMLYAK JAMES M | -2,487 | $126.24 | $313,959 |
| 2026-01-30 | ZEMLYAK JAMES M | +5,644 | - | - |
| 2026-01-29 | ZEMLYAK JAMES M | -9 | $123.9 | $1,115 |
| 2026-01-26 | Nesi Victor | -25,591 | - | - |
| 2026-01-26 | Nesi Victor | -11,981 | $129.2 | $1,547,945 |
| 2026-01-26 | Nesi Victor | +25,591 | - | - |
| 2026-01-13 | Rubulotta David | -2,302 | - | - |
| 2026-01-13 | Rubulotta David | -910 | $125.22 | $113,950 |
| 2026-01-13 | Rubulotta David | +2,302 | - | - |
| 2026-01-13 | Raymond Charles Bradford | -20,927 | - | - |
| 2026-01-13 | Raymond Charles Bradford | -10,456 | $125.22 | $1,309,300 |
| 2026-01-13 | Raymond Charles Bradford | +20,927 | - | - |
| 2026-01-13 | McDuffie Brantley | -2,094 | - | - |
| 2026-01-13 | McDuffie Brantley | -840 | $125.22 | $105,185 |
| 2026-01-13 | McDuffie Brantley | +2,094 | - | - |
| 2026-01-13 | Marischen James M | -12,055 | - | - |
| 2026-01-13 | Marischen James M | -5,749 | $125.22 | $719,890 |
| 2026-01-13 | Marischen James M | +12,055 | - | - |
| 2026-01-13 | Michaud Thomas B. | -14,965 | - | - |
| 2026-01-13 | Michaud Thomas B. | -7,490 | $125.22 | $937,898 |
| 2026-01-13 | Michaud Thomas B. | +14,965 | - | - |
| 2026-01-13 | Fisher Mark P | -11,335 | - | - |
| 2026-01-13 | Fisher Mark P | -6,695 | $125.22 | $838,348 |
| 2026-01-13 | Fisher Mark P | +11,335 | - | - |
| 2026-01-13 | SLINEY DAVID D | -10,854 | - | - |
| 2026-01-13 | SLINEY DAVID D | -3,677 | $125.22 | $460,434 |
| 2026-01-13 | SLINEY DAVID D | +10,854 | - | - |
| 2026-01-13 | ZEMLYAK JAMES M | -25,570 | - | - |
| 2026-01-13 | ZEMLYAK JAMES M | -10,143 | $125.22 | $1,270,106 |
| 2026-01-13 | ZEMLYAK JAMES M | +25,570 | - | - |
| 2026-01-13 | KRUSZEWSKI RONALD J | -52,427 | - | - |
| 2026-01-13 | KRUSZEWSKI RONALD J | -21,974 | $125.22 | $2,751,584 |
| 2026-01-13 | KRUSZEWSKI RONALD J | +52,427 | - | - |
| 2026-01-13 | REICHERT CHRISTOPHER K | -7,304 | - | - |
| 2026-01-13 | REICHERT CHRISTOPHER K | -2,202 | $125.22 | $275,734 |
| 2026-01-13 | REICHERT CHRISTOPHER K | +7,304 | - | - |
| 2025-12-26 | ZEMLYAK JAMES M | -10,000 | - | - |
| 2025-12-26 | KRUSZEWSKI RONALD J | -10,000 | - | - |
| 2025-12-22 | SLINEY DAVID D | -750 | - | - |
| 2025-12-18 | Marischen James M | -395 | - | - |
| 2025-12-08 | Nesi Victor | -19,401 | - | - |
| 2025-12-08 | Nesi Victor | +19,401 | - | - |
| 2025-12-08 | KRUSZEWSKI RONALD J | -10,000 | - | - |
| 2025-11-20 | WEISEL THOMAS W | -255 | - | - |
| 2025-11-13 | PEACOCK DAVID A | -3,000 | - | - |
| 2025-11-13 | Fisher Mark P | -1,000 | - | - |
| 2025-11-10 | ZEMLYAK JAMES M | -10,000 | - | - |